A Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus - Trial NCT06015737
Access comprehensive clinical trial information for NCT06015737 through Pure Global AI's free database. This Phase 3 trial is sponsored by AstraZeneca and is currently Not yet recruiting. The study focuses on Cutaneous Lupus Erythematosus. Target enrollment is 230 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
AstraZeneca
Timeline & Enrollment
Phase 3
Oct 25, 2023
Dec 16, 2026
Primary Outcome
Number of participants with Cutaneous Lupus Erythematosus Disease Area and Severity Index - Activity (CLASI-A) CLASI-A Responder Index-7 (CRI- 7) response (United States),Number of participants with CLASI-70 response (European Union and Rest of the World)
Summary
This study aims to evaluate the efficacy and safety of a subcutaneous (SC) treatment regimen
 of dose A of anifrolumab versus placebo in adult participants with cutaneous lupus
 erythematosus (CLE).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06015737
Non-Device Trial